The FDA is what it is, we can’t change them. We have to
The FDA is what it is, we can’t change them. We have to find a way to navigate this so there process does not become a roadblock. Many years ago I felt strongly the GvHD indication should have been put first. The reason is not that there is much revenue, but because it is a great base hit. Imagine if all other indications were built on an already FDA approved drug? The big problem now is we have a long list of huge indications with no approval on any of them. BP would not care if we were to take over the GvHD market, and would not realize we were heading to bigger things. The FDA, BP and investors look at the big claims of this drug and the reaction is prove it, because that sounds a little too sensational. The David vs Goliath scenario could have been avoided if our hunger could have been tempered to what we could realistically achieve.
Most small biotechs get bought or partnered with around phase 2, if they are at the phase 3 stage they failed to get partners at phase 2. That in my opinion is the second mistake made, we did not team up at phase 2 years ago in HIV. I am very hopeful that we are getting second chances with cancer and Nash. I don’t think about how long until approval for either, I think about the eyes on this drug at this phase.
I don’t feel we should slow roll some indications, I just think the self evaluation and realistic goals are in the back set to chasing the new shiny thing. Covid has the climate to bypass a difficult process because it is a pandemic, however we have somehow found a way to take the shortcuts and end up on the long road. However, I can’t stress this enough, this is a very unique situation. How many drugs are this safe, this effective against so many indications and under the umbrella of a tiny company run by a mechanical engineer? Do any of us really think what has been done so far is wrong? You can’t know because this is so bizarre.
12
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Shifts in Silver Mining: A New Face at Sunshine Awright, let's talk silver. No, not paper dollars, but the shiny stuff in the ground. Sunshine Silver Mining & Refining's just brought a guy named Mike Patterson onboard to shake things up with investor relations and corporate strategy. Sunshine's got big plans, you see. They're eyeing the restart of the Sunshine Mine,...
Continue Reading
The Changing Face of Tooth Replacement Let's dive into teeth. We're talking dentures, implants, and the rest of the gang that live in the world of full mouth replacements. Dr. Christopher Glenn Miller’s insights shared with HelloNation zero in on the evolution of tooth replacement options. Gone are the days of clunky dentures being your only shot. From sucking gum to...
Continue Reading
A Strategic Leap In Connection Products You know, in the business world, it's all about making those smart moves that position you right at the doorstep of growth. Midland Industries is doing just that with its recent acquisition of Pegasus Supply Group. While Midland didn't spill the beans on the financials, this takeover seems more than just a simple grab for assets....
Continue Reading
Drivers Warming Up to Fleet Safety Tech Seems like most fleet drivers these days are eyeing safety tech through a fresher lens. Gone are the days when grumbling about privacy was the anthem of the disgruntled. The latest Linxup survey claims a whopping 77% of commercial fleet pros have hopped onto the safety train, happily trading privacy qualms for the perks of solid...
Continue Reading
When Second Lady Usha Vance joins a summit, folks know it's a big deal. The Reagan Institute’s Education Summit is shaping up to be a showdown of ideas, tackling education’s role in a whirlwind of technological and political changes. This ain’t your average PTA meeting. We’re talking heavyweights like Utah Governor Spencer Cox and Colorado Governor Jared Polis...
Continue Reading
Tranter's Bold Move in Manufacturing No smoke and mirrors about it—Tranter's pulling out the big guns in Vänersborg with a shiny new 5,000-metric-ton press. And why not? As heat exchangers become hotter commodities, you've got to gear up to meet the demand or watch customers drift. This isn't just a new toy; it's a weapon for dominating growing markets. Precision and...
Continue Reading
Shifting Gears: A Closer Look at Immunic's New Direction It's not every day you witness a biotech outfit like Immunic making waves with a high-profile leadership shift. Today, they introduced Chitrang Davé as their Chief Data and Digital Officer. Why's this a big deal? Well, it's a signal that Immunic is dead serious about stepping into commercial territory. The Role and...
Continue Reading
Crushing the Competition: Adecoagro's New Acquisition When there's dirt under your fingernails and deals in the air, taking a strategic swing like Adecoagro just did can be a game-changer. Shelling out R$705 million (roughly US$136 million) in cash isn't what you'd call pocket change, but they're not new to ballsy moves. They've snapped up the Caarapó Mill, previously...
Continue Reading
Gearing Up for Sneak-Attack Thrills Look, some folks stock up on candy by October, but the real adrenaline junkies? They’re already on the road long before that, eyes set on hitting America's creepiest haunts. This year, the game isn't just October. Mark the date—September 11 is when the screams start pushing the limits of your vocal cords, thanks to America Haunts....
Continue Reading
Key Acquisition: Strengthening Global Presence Ignyte Insurance just added a major player to its roster with the acquisition of InsureMyTrip. No two ways about it, this move is about expanding their footprint in the booming travel and medical insurance sector. Now, if you've ever thought travel insurance was just fine print nobody reads, think again. This industry’s got...
Continue Reading
Top 5 Most Recently Viewed Articles
VanillaSoft Announces Key Leadership Changes Austin, Texas - VanillaSoft, a leading sales engagement technology company, has taken significant steps to enhance its leadership team. The recent appointments mark a strategic move aimed at driving the company’s growth and improving customer experiences. Paul McGee's Promotion to Senior Vice President In an exciting...
Continue Reading
Globe Life Reports Impressive Q3 Financial Results Globe Life Inc. (NYSE: GL) recently announced its financial results for the third quarter of 2024, marking significant growth compared to the previous year. The company reported a net income of $3.44 per diluted common share, a notable increase from $2.68 per diluted share in the same quarter of the prior year....
Continue Reading
TechnoMile’s Path to Growth: A Strategic Merger TechnoMile, an ambitious AI-powered platform for government contractors, has achieved remarkable growth over the years. This incredible journey took a significant leap forward with the recent merger with SIMS Software, a well-respected name in industrial security software. K1 Investment Management, a leading investor in...
Continue Reading
Rigel Pharmaceuticals Announces Employee Stock Options Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) has recently made headlines by granting new stock options to its employees, an action that reflects the company’s commitment to its workforce. This decision was made in alignment with NASDAQ Listing Rule 5635(c)(4), facilitating new employment compensations for the team at...
Continue Reading
Investigation into Applied Therapeutics, Inc. Recently, concerns have been raised regarding the performance and governance of Applied Therapeutics, Inc. (NASDAQ: APLT). Legal discussions have initiated an investigation focused on possible violations of federal securities laws, dedicated to protecting the interests of investors. Shocking Developments for Shareholders On...
Continue Reading